Navigation Links
Neuralstem files FDA application for first drug therapy
Date:11/17/2010

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

"This marks more than just a significant milestone for the company: we believe our compound represents the next generation of antidepressant treatment based on a new mechanism of action that may, for the first time, fundamentally modify the disease," said Neuralstem President & CEO Richard Garr. "NSI-189 also validates Neuralstem's proprietary neural stem cell screening approach as a source for discovering novel compounds that affect complex stem cell biology rather than a single molecular target."

"The antidepressants that are available today are based on the theory of serotonin deficiency," explained Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "NSI-189 is based on a new theory that chronic exposure to stress hormones can inhibit the growth of new neurons in certain regions of the brain. This can lead to hippocampal atrophy and depression. We believe that this neurogenic approach to brain self-repair may be applicable in multiple diseases including: Alzheimer's disease, mild cognitive impairment, dementia, schizophrenia, cognitive complications from diabetes, post-traumatic stress syndrome and traumatic brain injury, all of which are indications that the company intends to pursue with this new class of drugs."

About NS-189: Stimulating Neurogenesis To Address Central Nervous System Conditions

NS-189 is the first in a class of compounds that Neuralstem plans to develop into orally administered drugs. These appear to have the effect of "recruiting" the patient's own neural stem cells to repair or protect against damage to the Central Nervous System (CNS) from disease or injury.

NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in- vitro. In mice, NSI-189 both stimulated neurogenesis of the hippocampus and increased its overall volume as well. Therefore, NSI-189 may reverse the human hippocampal atrophy seen in major depression and schizophrenia. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).

The Neuralstem small molecule platform results from discoveries made through Neuralstem's ability to generate stable human neural stem cell lines suitable for screening large chemical libraries. The platform complements Neuralstem's cell therapy platform, in which brain and spinal cord stem cells are transplanted directly into diseased areas to repair and/or replace diseased or dead cells.

About the Trial

Neuralstem has filed an IND with the FDA to conduct two Phase I safety trials. The first trial will involve normal healthy volunteers testing the safety of escalating doses of a single administration of NSI-189. The second trial is designed to test the safety of escalating doses of daily administration for 28 days in depressed patients. The entire trial is expected to be approximately one year in duration.

Further information will be available on the Neuralstem website after the FDA approves the trial.


'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Related medicine news :

1. Neuralstem updates clinical trial progress
2. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
3. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
4. Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
5. Neuralstem updates ALS clinical trial progress
6. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
7. Facebook Profiles Dont Stretch the Truth
8. Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2009
9. Justice Department Files for Immediate Relief Regarding Conditions at Conway Human Development Center, in Conway, Arkansas
10. Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement
11. Scilabs Nutraceuticals Inc., Files Multimillion Dollar Suit Against Naturade for Fraudulent Business Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... According to ... In an industry filled with chemical-laden beauty products, one company is going against the ... for you: Mad Hippie. The rising star in the green space is proud to ...
(Date:5/26/2016)... Lake MN (PRWEB) , ... May 26, 2016 , ... ... Stance Angle chair , furniture that may support women during pregnancy. Potential benefits ... legs and feet, improved rest and comfort and healthier levels of sitting and standing. ...
(Date:5/25/2016)... (PRWEB) , ... May 26, 2016 , ... The United ... treatment of androgenetic alopecia in both men and women. To date, the company is ... with FDA clearance for any adult who suffers with androgenetic alopecia. , “This ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
(Date:5/25/2016)... Kansas City, MO (PRWEB) , ... May 25, 2016 , ... ... professional, collegiate, and amateur athletics, The National Center for Drug Free Sport (Drug Free ... Drug Free Sport”. This conference, to be held July 12 – 13 in Kansas ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
(Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
Breaking Medicine Technology: